Key result
Recurrent VTE in cancer patients linked to a ~219% increase in VTE-related hospitalizations.
Why the study?
Patients with cancer face a high risk of primary and recurrent venous thromboembolism, but healthcare utilization and costs related to recurrence required evaluation.
Does recurrent VTE increase healthcare utilization and costs compared to a single VTE event in patients with cancer?
Population
2,428 newly diagnosed cancer patients who developed VTE
Comparison
Recurrent VTE vs a single VTE event
Design
Retrospective database claims analysis
Follow-up
Mean = 9 months
Authors
Loading...
May heighten emphasis on VTE prevention in cancer to limit costs; extends observational data but remains hypothesis-generating.
Cohort (n=2,428)
Does recurrent VTE increase healthcare utilization and costs compared to a single VTE event in patients with cancer?
Relative Risk: 3.19 (95% CI 2.93–3.47)
Recurrent VTE in cancer patients is associated with significantly higher healthcare resource utilization and costs, primarily driven by hospitalizations.
Khorana et al. (2019) conducted a cohort in Cancer with venous thromboembolism (n=2,428). Recurrent VTE vs. No VTE recurrence was evaluated on VTE-related hospitalizations (RR 3.19, 95% CI 2.93-3.47). Recurrent VTE in cancer patients was associated with 3.19-times more VTE-related hospitalizations (RR 3.19; 95% CI 2.93-3.47) and $29,142 higher VTE-related healthcare costs per patient per year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: